Biochemical Recurrence of Prostate Cancer: Initial Results with [<sup>18</sup>F]PSMA-1007 PET/CT.
Where this comes from
- Record sourced from PubMed, PMID 29419475.
- Also identified by DOI 10.2967/jnumed.117.196329.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Biochemical recurrence (BCR) is a concern for prostate cancer patients after local treatment. <sup>68</sup>Ga-labeled prostate-specific membrane antigen (PSMA) ligands have significantly improved prostate cancer imaging. However, several <sup>18</sup>F-labeled ligands that were developed as fluorinated tracers might present advantages. In this study, we analyzed the potential of <sup>18</sup>F-PSMA-1007 in patients with BCR. <b>Methods:</b> Twelve patients with BCR after local treatment underwent PET/CT scans 1 and 3 h after injection of <sup>18</sup>F-PSMA-1007. <b>Results:</b><sup>18</sup>F-PSMA-1007 PET/CT detected lesions in 9 of 12 patients (75%). A significant difference was observed when comparing the tracer uptake in <sup>18</sup>F-PSMA-1007-positive lesions 1 and 3 h after injection (median SUV<sub>max</sub>, 7.00 vs. 11.34; <i>P</i> < 0.001; <i>n</i> = 76). Forty-four (88%) of 50 <sup>18</sup>F-PSMA-1007-positive lymph nodes had a short-axis diameter of less than 8 mm. <b>Conclusion:</b> In this pilot study, <sup>18</sup>F-PSMA-1007 PET/CT presented high potential for localization of recurrent disease in prostate cancer patients with BCR.
Medical subject headings
- Fluorine Radioisotopes
- Niacinamide
- Oligopeptides
- Positron Emission Tomography Computed Tomography
- Prostatic Neoplasms